


GSK in Belgium

Who are we?

We are a global biopharma company with a purpose to **unite science, technology and talent** to get ahead of disease together.

We aim to positively impact the health of **2.5 billion people** over the next 10 years.





Rixensart – This historic site houses our largest vaccine research and development (R&D) unit. The names of our vaccines developed here end with **–RIX**.

We have acquired unique international expertise in the fields of adjuvants and bacterial and viral infections.

> 20

candidate vaccines in research & development as well as
> 20 scientific collaborations with Belgian universities and research centres.

37

clinical trials in 2022 in Belgium, involving 1,800 volunteers.

> €1

billion invested in R&D in 2022.

Gembloux – Construction of a new, unique, ultra-modern centre dedicated to the storage and export of our vaccines.



Belgium: the heart of our vaccines

We have 3 important vaccines sites in Belgium.

Our infrastructure represents **the largest, integrated industrial network of vaccines**, from early discovery, through development, all manufacturing steps and export.



Wavre – This site is the heart of our vaccines business. It is **the largest vaccine production site in the world**, equivalent to

70 football fields.

Our colleagues responsible for the distribution of our vaccines and medicines in Belgium and in Luxembourg are also located in Wavre.

Our vaccines are exported to >160 countries.

We are the largest Walloon exporter: our vaccines account for >10% of exports.


70% of manufacturing time is dedicated to quality controls.



What we do

We produce **innovative vaccines** and **specialty medicines** to prevent and treat diseases.

Our research focuses on the science of the immune system, human genetics and cutting-edge technologies.



Our collaborators in Belgium

Our **Rixensart**, **Wavre** and **Gembloux** sites count **9,000 collaborators**, including 1,800 scientific researchers, representing >80 nationalities.

22%
workers.

35%
employees.

43%
managers.

Our sustainable development strategy

A healthy planet for healthy people.

To support GSK's vision, we focus on 4 areas in Belgium: **Energy & Carbon**, **Water**, **Waste** and **Biodiversity**.

Our ambitions for 2030:

- to be carbon neutral and
- have a net positive impact on nature



Our commitment to Global Health

GSK will invest **> €1 billion over the next 10 years** to accelerate health-focused R&D in developing countries.

We have always been **top of the Access to Medicine Index** since its creation.

Every minute, a child dies of malaria in Sub-Saharan Africa. Our **malaria vaccine** is the 1st vaccine approved and the only vaccine against a human parasite. It was developed in Rixensart, and is currently manufactured there. This vaccine was also amongst the finalists of the *essencia* Innovation Award in 2022.

GSK is one of the main suppliers of vaccines for

unicef



Gavi
The Vaccine Alliance



Ahead together

Want to find out more?

 be.gsk.com

The GSK logo is displayed in a bold, sans-serif font. The letters 'G' and 'S' are a darker orange, while the 'K' is a lighter, more vibrant orange. The letters are closely spaced and have a slight shadow effect.

External Communication and Public Affairs:

Elisabeth Van Damme | elisabeth.evandamme@gsk.com | +32 (0)478 27 26 41

GSK Vaccines | Avenue Fleming 20 – 1300 Wavre, Belgium

©GSK December 2022

Design: visible.be (23955)

Printed on FSC certified paper

CREDIT MIX SGSCH-COC-006801